

SUPPORTING INFECTIOUS DISEASE RESEARCH

Product Information Sheet for NR-48769

Cryptococcus neoformans, Strain KN99α

Catalog No. NR-48769

For research use only. Not for human use.

Contributor:

Joseph Heitman, Professor, Molecular Genetics and Microbiology Department, Duke University, Durham, North Carolina, USA

Manufacturer:

BEI Resources

Product Description:

Classification: Filobasidiaceae, Cryptococcus

Species: Cryptococcus neoformans

Strain: KN99α (also referred to as 10B9#3)

Mating Type: α1

<u>Original Source</u>: *Cryptococcus neoformans (C. neoformans),* strain KN99α was derived from strain H99O (BEI Resources NR-48767), after passage in the rabbit model of central nervous system infection.² *C. neoformans,* strain H99 was isolated from the cerebrospinal fluid of a human male who had been treated for Hodgkin's disease in North Carolina, USA on February 14, 1978.¹ After an unknown number of passages, strain H99 was reported to lose virulence and was subsequently passaged through the rabbit model of infection to increase its virulence. It was renamed as H99O and frozen in 1994.¹

Comments: C. neoformans var. grubii, strain H99O (H99) was sequenced in 2014 through a collaboration between Duke University and the Broad Institute² (NCBI BioProject: PRJNA411). Strain H99O is the progenitor of nine phenotypic variants that display either increased or decreased mating ability, melanization and virulence.¹

BEI Resources Number	Strain Name	Mating ability/ Melanization/ Virulence
NR-48767	H99O	N/A
NR-48768	KN99a	Increased
NR-48769	ΚΝ99α	Increased
NR-48770	H99F	Increased
NR-48771	H99C	Decreased
NR-48772	H99S	Increased
NR-48773	H99W	Decreased
NR-48774	H99ED	Decreased
NR-48775	H99E	Decreased
NR-48776	YL99α	Increased
NR-48777	YL99a	Increased

C. neoformans, strain KN99α was derived from strain H99O concurrently with the congenic strain KN99a (BEI Resources NR-48768). The congenic pair was created by backcrossing strain H99O with strain H99F (BEI Resources NR-48770).¹

There are currently two species, *C. neoformans* and *C. gattii* in the Cryptococcus species complex. These species are best

recognized as the agents of cryptococcosis, an AIDS-defining illness. *C. neoformans* has been widely associated with avian excreta. C. neoformans is divided into two varieties, *C. neoformans* var. grubii (serotype A) and *C. neoformans* var neoformans (serotype D). In the current classification scheme, there are five distinct lineages recognized, named VNI, VNII, VNB, VNIII and VNIV. The two varieties (neoformans and grubii) are able to recombine and produce diploid or aneuploid intervarietal AD hybrids.

Material Provided:

Each vial contains approximately 0.5 mL of *C. neoformans* in 20% glycerol.

Packaging/Storage:

NR-48769 was packaged aseptically in cryovials and is provided frozen on dry ice. The product should be stored at cryogenic temperature (-130°C or colder), preferably in the vapor phase of a liquid nitrogen freezer. If liquid nitrogen storage facilities are not available, frozen cryovials may be stored at -70°C or colder for approximately one week.

Growth Conditions:

Media:

Yeast Mold broth or equivalent Yeast Mold agar or equivalent

Incubation:

Temperature: 25°C to 30°C Atmosphere: Aerobic

Propagation:

- Keep vial frozen until ready for use; thaw rapidly in a waterbath at 25°C to 30°C. Typically, this takes less than 5 minutes.
- Immediately after thawing, inoculate an agar plate with approximately 40 µL of thawed culture and/or transfer the entire thawed aliquot into a single tube of broth.
- Incubate the plate and/or tube at 25°C to 30°C for 2 to 4 days.

Citation:

Acknowledgment for publications should read "The following reagent was obtained through BEI Resources, NIAID, NIH: *Cryptococcus neoformans*, Strain KN99α, NR-48769."

Biosafety Level: 2

Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the following publication: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, and National Institutes of Health. Biosafety in Microbiological and Biomedical Laboratories. 5th ed. Washington, DC: U.S. Government Printing Office, 2009; see www.cdc.gov/biosafety/publications/bmbl5/index.htm.

Disclaimers:

You are authorized to use this product for research use only. It is not intended for human use.

BEI Resources www.beiresources.org E-mail: contact@beiresources.org

Tel: 800-359-7370 Fax: 703-365-2898



Product Information Sheet for NR-48769

SUPPORTING INFECTIOUS DISEASE RESEARCH

Use of this product is subject to the terms and conditions of the BEI Resources Material Transfer Agreement (MTA). The MTA is available on our Web site at www.beiresources.org.

While BEI Resources uses reasonable efforts to include accurate and up-to-date information on this product sheet, neither ATCC® nor the U.S. Government makes any warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. Neither ATCC® nor the U.S. Government warrants that such information has been confirmed to be accurate.

This product is sent with the condition that you are responsible for its safe storage, handling, use and disposal. ATCC® and the U.S. Government are not liable for any damages or injuries arising from receipt and/or use of this product. While reasonable effort is made to ensure authenticity and reliability of materials on deposit, the U.S. Government, ATCC®, their suppliers and contributors to BEI Resources are not liable for damages arising from the misidentification or misrepresentation of products.

Use Restrictions:

This material is distributed for internal research, non-commercial purposes only. This material, its product or its derivatives may not be distributed to third parties. Except as performed under a U.S. Government contract, individuals contemplating commercial use of the material, its products or its derivatives must contact the contributor to determine if a license is required. U.S. Government contractors may need a license before first commercial sale.

References:

- Janbon, G., et al. "Analysis of the Genome and Transcriptome of *Cryptococcus neoformans* var. *grubii* Reveals Complex RNA Expression and Microevolution Leading to Virulence Attenuation." <u>PLoS Genet.</u> 10 (2014): e1004261. PubMed: 24743168.
- 2. Heitman, J., Personal Communication.
- Cogliati, M. "Global Molecular Epidemiology of Cryptococcus neoformans and Cryptococcus gattii: An Atlas of the Molecular Types." <u>Scientifica</u> 2013; 2013.675213. PubMed: 24278784.

ATCC® is a trademark of the American Type Culture Collection.

E-mail: contact@beiresources.org

Tel: 800-359-7370 Fax: 703-365-2898